BOSTON--(BUSINESS WIRE)--MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced the successful completion of an analytical validation study of its MetaSite Breast™ clinical test, which demonstrated analytical precision greater than 97%. MetaSite Breast™ is a next generation driver-based prognostic test to predict the risk of developing metastatic disease in patients with ER+ invasive breast cancer. This information allows physicians to optimize treatment decisions and improve patient outcomes.
Help employers find you! Check out all the jobs and post your resume.
